Risk mitigation in academic drug discovery

Ellinger, Bernhard; Gribbon, Philip

doi:10.1517/17460441.2016.1152257

Cited by 5 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditionally, academic drug discovery is aimed at better understanding the underlying biology of a disease, and so AB1 and AB2 might be most important 16,36 . However, depending on the project goals, such as spin-off formation or licensing, AB4 and/or AB5 can also become crucial to increase the value of a project.…”

Section: Box 1 | Frequency Of Target Assessment Aspects Used In Academentioning

confidence: 99%

“…Applying the GOT-IT workflow Establishing a project plan. Entering drug discovery projects with a strategic plan that clearly outlines goals and expectations, milestones and go/no-go decision points helps to reduce operational risks and facilitates resource management 16,36,161,162 . Even at this early stage, several key factors for project success can be established (at least tentatively), such as identifying collaboration partners, target indication(s) and medical needs, as well as relevant biological test systems, tool compounds and biomarkers.…”

Section: Biomarker Identification and Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Improving target assessment in biomedical research: the GOT-IT recommendations

Emmerich¹,

Martínez-Gamboa

Hofmann

et al. 2020

Nat Rev Drug Discov

132

View full text Add to dashboard Cite

Academic research plays a key role in identifying new drug targets, including understanding target biology and links between targets and disease states. To lead to new drugs, however, research must progress from purely academic exploration to the initiation of efforts to identify and test a drug candidate in clinical trials, which are typically conducted by the biopharma industry. This transition can be facilitated by a timely focus on target assessment aspects such as target-related safety issues, druggability and assayability, as well as the potential for target modulation to achieve differentiation from established therapies. Here, we present recommendations from the GOT-IT working group, which have been designed to support academic scientists and funders of translational research in identifying and prioritizing target assessment activities and in defining a critical path to reach scientific goals as well as goals related to licensing, partnering with industry or initiating clinical development programmes. Based on sets of guiding questions for different areas of target assessment, the GOT-IT framework is intended to stimulate academic scientists’ awareness of factors that make translational research more robust and efficient, and to facilitate academia–industry collaboration.

show abstract

Section: Box 1 | Frequency Of Target Assessment Aspects Used In Academentioning

confidence: 99%

Section: Biomarker Identification and Developmentmentioning

confidence: 99%

Improving target assessment in biomedical research: the GOT-IT recommendations

Emmerich¹,

Martínez-Gamboa

Hofmann

et al. 2020

Nat Rev Drug Discov

132

View full text Add to dashboard Cite

show abstract

“…These factors, and an uptick in NIH funding of translational science, have served to fuel a build-out of academic drug discovery (ADD) centers, in terms of both number (up to nearly 100 centers from only about a dozen roughly a decade ago) and sophistication (Arrowsmith 2011a,b;Arrowsmith & Miller 2013). ADD centers are frequently staffed by a large fraction of professionals who previously worked in the pharmaceutical industry (Slusher et al 2013, Ellinger & Gribbon 2016. With this infrastructure, ADD centers can now be engaged in early drug discovery work, and increasingly, pharmaceutical companies are happy for these activities to be pursued at ADD centers, as they seek to license later-stage, de-risked programs for clinical development.…”

Section: Academic Drug Discovery Centersmentioning

confidence: 99%

“…However, a completely self-sustained academic drug discovery can be enabled only in a scenario where funding can be found to support clinical development. animal models (Ellinger & Gribbon 2016, Palmer & Chaguturu 2017. With such diverse input, highly novel solutions for problems can arise almost organically.…”

Section: Academic Drug Discovery Organization and Philosophymentioning

confidence: 99%

“…Significant issues need to be addressed to enable ADD endeavors to fulfill their potential. First, there is an ethical debate concerning institutional conflict of interest when commercializing academic research and how that may impact program choices and publication strategies (Ellinger & Gribbon 2016, Van Norman & Eisenkot 2017. Second, the issue of defining the funding model to cover the relatively high start-up costs involved in establishing ADD centers must be addressed, as well as the issue of identifying sustainable funding for expensive investigational new drugs and new drug applications required for preclinical and clinical studies.…”

Section: Charities and Foundationsmentioning

confidence: 99%

See 1 more Smart Citation

Academic Discovery of Anticancer Drugs: Historic and Future Perspectives

Carugo

Draetta

2019

Annu. Rev. Cancer Biol.

View full text Add to dashboard Cite

The identification and prosecution of meritorious anticancer drug targets and the discovery of clinical candidates represent an extraordinarily time- and resource-intensive process, and the current failure rate of late-stage drugs is a critical issue that must be addressed. Relationships between academia and industry in drug discovery and development have continued to change over time as a result of technical and financial challenges and, most importantly, to the objective of translating impactful scientific discoveries into clinical opportunities. This Golden Age of anticancer drug discovery features an increased appreciation for the high-risk, high-innovation research conducted in the nonprofit sector, with the goals of infusing commercial drug development with intellectual capital and curating portfolios that are financially tenable and clinically meaningful. In this review, we discuss the history of academic-industry interactions in the context of antidrug discovery and offer a view of where these interactions are likely headed as we continue to reach new horizons in our understanding of the immense complexities of cancer biology.

show abstract